Methods for treating epilepsy
Provided herein are methods of treating, preventing, ameliorating or managing a nonsense mutation mediated epileptic disease, comprising administering a 1,2,4-oxadiazole benzoic acid to a patient having a nonsense mutation mediated epileptic disease. In particular, provided herein are methods of treating, preventing, ameliorating or managing a CDKL5 and/or SCN1A (Dravet syndrome) nonsense mutation mediated epileptic disease.
1. A method for treating, ameliorating or managing a nonsense mutation mediated epileptic disease associated with a SCN1A nonsense mutation, comprising administering an effective amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]benzoic acid or a pharmaceutically acceptable salt thereof to a patient having the nonsense mutation mediated epileptic disease.
2. The method of claim 1 , wherein the salt is selected from the group consisting of a magnesium salt, a potassium salt, a sodium salt, a tromethamine salt, an L-lysine salt, an L-arginine salt, an N-methyl glucamine salt and an L-histidine salt.
3. The method of claim 1 , wherein the epileptic disease is associated with a SCN1A nonsense mutation selected from the group consisting of W192X, R222X, R568X, R701X, R854X, K1017X, W1261X, R1213X, W1408X, W952X, W1284X, S219fsX275, K100fsX1107, L1670fsX1107, and S1846fsX1856.
4. The method of claim 1 , wherein the epileptic disease is drug-resistant epilepsy.
5. The method of claim 1 , wherein the nonsense mutation mediated epileptic disease is Dravet syndrome.
6. The method of claim 2 , wherein the nonsense mutation mediated epileptic disease is Dravet syndrome.
7. The method of claim 3 , wherein the epileptic disease is Dravet syndrome.
8. The method of claim 4 , wherein the epileptic disease is Dravet syndrome.